Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Enrollment complete in Palatin's bremelanotide Phase 2B trial for FSD

Palatin Technologies, Inc. today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction.

9 Mar 2012

S1 submits Lorexys IND application for HSDD and Female Sexual Dysfunction treatment

S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

21 Feb 2012

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

19 Jan 2012

Ampio announces two new European patents for Zertane combination therapy

Ampio Pharmaceuticals, Inc., today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane with any erectile dysfunction drug of the PDE5 inhibitors family such as sildenafil, tadalafil and the likes and for a combination of Zertane with compounds that reduce the side effects of tramadol.

18 Jan 2012

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

BioSante listed on NASDAQ Biotechnology Index

BioSante Pharmaceuticals, Inc. today announced that it has been added to the NASDAQ Biotechnology Index, effective prior to the stock market open today, November 21, 2011.

21 Nov 2011

Switching or adding antidepressants does not exacerbate side effects

Patients with major depression who fail to see improvement after taking an antidepressant often have their initial medication switched or combined with a second drug. Many clinicians weigh the possibility of adverse side effects when deciding between strategies. New research in the latest issue of General Hospital Psychiatry now suggests one strategy may not be any more likely to be harmful than the other.

19 Nov 2011

Male breast cancer patients report tamoxifen side effects

About half of male breast cancer patients who take the drug tamoxifen to prevent their disease from returning report side effects such as weight gain and sexual dysfunction, which prompts more than 20 percent of them to discontinue treatment, according to researchers at The University of Texas MD Anderson Cancer Center.

17 Nov 2011

Additional results from BioSante's LibiGel pK study on HSDD

BioSante Pharmaceuticals, Inc., today announced additional results from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study. Top line data from this study were announced on September 12, 2011.

16 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

BioSante third quarter net loss increases to $12.7 million

BioSante Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company's pipeline.

9 Nov 2011

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma, Inc. today reported financial and operating results for the third quarter ended September 30, 2011.

8 Nov 2011

Bike riding cuts off blood flow to men's genitals

Is it just an urban myth, or can long-term bike riding cause sexual dysfunction in men? Previous studies have not shed much light on the question, says Dr. Craig Niederberger, professor and head of urology at the University of Illinois at Chicago College of Medicine, because they have not shown whether bike riding actually cuts off blood flow to men's genitals.

7 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Studies find less vitamin D intake among menopausal women

A healthy diet is especially important during the menopause - a period in which the risk of suffering from health problems increases. Various studies analyse the diet of peri- and postmenopausal women in Spain alongside the troubles that come with this transition. The results show that all of those groups studied have a deficient intake of vitamin D.

21 Oct 2011

USPTO issues patent to Rexahn's new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."

13 Oct 2011

DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study

BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.

11 Oct 2011

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.

29 Sep 2011

Role of email advice in patients with sexual problems

More than two-thirds of men who contacted an email advice service run by a leading sexual advice charity had erection problems, which were frequently linked to loss of sex drive, according to research in the October issue of IJCP, the International Journal of Clinical Practice.

23 Sep 2011